142 related articles for article (PubMed ID: 16485114)
1. The vitamin D analogue BXL-628 inhibits growth factor-stimulated proliferation and invasion of DU145 prostate cancer cells.
Marchiani S; Bonaccorsi L; Ferruzzi P; Crescioli C; Muratori M; Adorini L; Forti G; Maggi M; Baldi E
J Cancer Res Clin Oncol; 2006 Jun; 132(6):408-16. PubMed ID: 16485114
[TBL] [Abstract][Full Text] [Related]
2. Non-genomic effects of the androgen receptor and vitamin D agonist are involved in suppressing invasive phenotype of prostate cancer cells.
Bonaccorsi L; Marchiani S; Ferruzzi P; Muratori M; Crescioli C; Forti G; Maggi M; Baldi E
Steroids; 2006 Apr; 71(4):304-9. PubMed ID: 16289173
[TBL] [Abstract][Full Text] [Related]
3. Gefitinib ('IRESSA', ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3 K/AKT activation.
Bonaccorsi L; Marchiani S; Muratori M; Forti G; Baldi E
J Cancer Res Clin Oncol; 2004 Oct; 130(10):604-14. PubMed ID: 15258753
[TBL] [Abstract][Full Text] [Related]
4. Vitamin D3 analogue inhibits keratinocyte growth factor signaling and induces apoptosis in human prostate cancer cells.
Crescioli C; Maggi M; Luconi M; Vannelli GB; Salerno R; Sinisi AA; Bonaccorsi L; Ferruzzi P; Barni T; Forti G; Serio M
Prostate; 2002 Jan; 50(1):15-26. PubMed ID: 11757032
[TBL] [Abstract][Full Text] [Related]
5. Effect of a vitamin D3 analogue on keratinocyte growth factor-induced cell proliferation in benign prostate hyperplasia.
Crescioli C; Maggie M; Vannelli GB; Luconi M; Salerno R; Barni T; Gulisano M; Forti G; Serio M
J Clin Endocrinol Metab; 2000 Jul; 85(7):2576-83. PubMed ID: 10902811
[TBL] [Abstract][Full Text] [Related]
6. Signaling mechanisms that mediate invasion in prostate cancer cells.
Bonaccorsi L; Marchiani S; Muratori M; Carloni V; Forti G; Baldi E
Ann N Y Acad Sci; 2004 Dec; 1028():283-8. PubMed ID: 15650253
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of spontaneous and androgen-induced prostate growth by a nonhypercalcemic calcitriol analog.
Crescioli C; Ferruzzi P; Caporali A; Mancina R; Comerci A; Muratori M; Scaltriti M; Vannelli GB; Smiroldo S; Mariani R; Villari D; Bettuzzi S; Serio M; Adorini L; Maggi M
Endocrinology; 2003 Jul; 144(7):3046-57. PubMed ID: 12810561
[TBL] [Abstract][Full Text] [Related]
8. Effect of keratinocyte growth factor on cell viability in primary cultured human prostate cancer stromal cells.
Huang YW; Wang LS; Chang HL; Ye W; Shu S; Sugimoto Y; Lin YC
J Steroid Biochem Mol Biol; 2006 Jul; 100(1-3):24-33. PubMed ID: 16854582
[TBL] [Abstract][Full Text] [Related]
9. [P2Y purinergic receptor activated PI-3K/Akt signaling pathway in regulation of growth and invasion of prostatic cancer].
Wang YX; Shi YH; Gong LH; Li Y; Heng WJ; You JF; Zhong HH; Fang WG
Zhonghua Bing Li Xue Za Zhi; 2007 Oct; 36(10):681-6. PubMed ID: 18194602
[TBL] [Abstract][Full Text] [Related]
10. Influence of novel KGFR tyrosine kinase inhibitors on KGF-mediated proliferation of breast cancer.
Mehta M; Kesinger JW; Zang XP; Lerner ML; Brackett DJ; Brueggemeier RW; Li PK; Pento JT
Anticancer Res; 2010 Dec; 30(12):4883-9. PubMed ID: 21187466
[TBL] [Abstract][Full Text] [Related]
11. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.
Shukla S; Maclennan GT; Hartman DJ; Fu P; Resnick MI; Gupta S
Int J Cancer; 2007 Oct; 121(7):1424-32. PubMed ID: 17551921
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells.
Swamy N; Chen TC; Peleg S; Dhawan P; Christakos S; Stewart LV; Weigel NL; Mehta RG; Holick MF; Ray R
Clin Cancer Res; 2004 Dec; 10(23):8018-27. PubMed ID: 15585637
[TBL] [Abstract][Full Text] [Related]
13. Human bladder as a novel target for vitamin D receptor ligands.
Crescioli C; Morelli A; Adorini L; Ferruzzi P; Luconi M; Vannelli GB; Marini M; Gelmini S; Fibbi B; Donati S; Villari D; Forti G; Colli E; Andersson KE; Maggi M
J Clin Endocrinol Metab; 2005 Feb; 90(2):962-72. PubMed ID: 15572423
[TBL] [Abstract][Full Text] [Related]
14. SU6668 modulates prostate cancer progression by downregulating MTDH/AKT signaling pathway.
Qian B; Yao Y; Liu C; Zhang J; Chen H; Li H
Int J Oncol; 2017 May; 50(5):1601-1611. PubMed ID: 28339027
[TBL] [Abstract][Full Text] [Related]
15. Tetrandrine suppresses proliferation, induces apoptosis, and inhibits migration and invasion in human prostate cancer cells.
Liu W; Kou B; Ma ZK; Tang XS; Lv C; Ye M; Chen JQ; Li L; Wang XY; He DL
Asian J Androl; 2015; 17(5):850-3. PubMed ID: 25677131
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor effect of ascorbic acid, lysine, proline, arginine, and epigallocatechin gallate on prostate cancer cell lines PC-3, LNCaP, and DU145.
Roomi MW; Ivanov V; Kalinovsky T; Niedzwiecki A; Rath M
Res Commun Mol Pathol Pharmacol; 2004; 115-116():251-64. PubMed ID: 17564322
[TBL] [Abstract][Full Text] [Related]
17. Serotonin activates MAP kinase and PI3K/Akt signaling pathways in prostate cancer cell lines.
Dizeyi N; Hedlund P; Bjartell A; Tinzl M; Austild-Taskén K; Abrahamsson PA
Urol Oncol; 2011; 29(4):436-45. PubMed ID: 19926313
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia.
Crescioli C; Ferruzzi P; Caporali A; Scaltriti M; Bettuzzi S; Mancina R; Gelmini S; Serio M; Villari D; Vannelli GB; Colli E; Adorini L; Maggi M
Eur J Endocrinol; 2004 Apr; 150(4):591-603. PubMed ID: 15080791
[TBL] [Abstract][Full Text] [Related]
19. CX3CL1 increases invasiveness and metastasis by promoting epithelial-to-mesenchymal transition through the TACE/TGF-α/EGFR pathway in hypoxic androgen-independent prostate cancer cells.
Tang J; Xiao L; Cui R; Li D; Zheng X; Zhu L; Sun H; Pan Y; Du Y; Yu X
Oncol Rep; 2016 Feb; 35(2):1153-62. PubMed ID: 26718770
[TBL] [Abstract][Full Text] [Related]
20. Substitution at carbon 2 of 19-nor-1α,25-dihydroxyvitamin D3 with 3-hydroxypropyl group generates an analogue with enhanced chemotherapeutic potency in PC-3 prostate cancer cells.
Iglesias-Gato D; Zheng S; Flanagan JN; Jiang L; Kittaka A; Sakaki T; Yamamoto K; Itoh T; Lebrasseur NK; Norstedt G; Chen TC
J Steroid Biochem Mol Biol; 2011 Nov; 127(3-5):269-75. PubMed ID: 21911059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
